Rather than advocating routine adrenal screening for all at-risk patients, which requires validation from larger studies, we suggest clinicians consider adrenal function testing (e.g., morning cortisol, ACTH) in cancer patients with unexplained HFpEF, especially post-therapy, to facilitate timely intervention. This evidence concerns the gene POMC and cancer.